We are live on ! Find out more
TCM

Tang Capital Management Portfolio holdings

AUM $1.97B
1-Year Est. Return 125.1%
This Fund
S&P 500
This Quarter Est. Return
+16.47%
1 Year Est. Return
+125.1%
3 Year Est. Return
+474.48%
5 Year Est. Return
+595.08%
10 Year Est. Return
+2,831.44%
AUM
$1.4B
AUM Growth
+$418M
Cap. Flow
+$336M
Cap. Flow %
23.99%
Top 10 Hldgs %
35.88%
Holding
162
New
35
Increased
43
Reduced
14
Closed
8

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$36.7M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$30.7M
3
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$27.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$26.7M
5
IMCR icon
Immunocore
IMCR
+$25.5M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24.4M
2
DVAX
Dynavax Technologies
DVAX
+$6.61M
3
BEAM icon
Beam Therapeutics
BEAM
+$2.58M
4
CRSP icon
CRISPR Therapeutics
CRSP
+$2.54M
5
INBX icon
Inhibrx
INBX
+$2.37M

Sector Composition

Rank Sector Weight
1 Healthcare 95.59%
2 Technology 1.47%
3 Communication Services 1.22%
4 Real Estate 0.34%
5 Financials 0.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARE icon
76
Alexandria Real Estate Equities
ARE
$8.56B
$4.75M 0.34%
40,000
– –
IOVA icon
77
Iovance Biotherapeutics
IOVA
$2.87B
$4.7M 0.34%
500,000
– –
ALMS
78
Alumis Inc
ALMS
$3.52B
$4.56M 0.33%
+426,594
New +$5.17M
SEER icon
79
Seer Inc
SEER
$120M
$4.53M 0.32%
2,300,000
– –
ARVN icon
80
Arvinas
ARVN
$572M
$4.43M 0.32%
180,000
– –
BEAM icon
81
Beam Therapeutics
BEAM
$2.84B
$4.17M 0.3%
170,000
-100,000
-37% -$2.58M
SNY icon
82
Sanofi
SNY
$104B
$4.03M 0.29%
+70,000
New +$3.78M
CCCC icon
83
C4 Therapeutics
CCCC
$412M
$3.99M 0.29%
700,000
+500,000
+250% +$3.01M
HRTX icon
84
Heron Therapeutics
HRTX
$92.9M
$3.68M 0.26%
1,850,000
– –
HELP
85
Cybin Inc
HELP
$720M
$3.56M 0.25%
+400,000
New +$3.96M
TYRA icon
86
Tyra Biosciences
TYRA
$1.58B
$3.53M 0.25%
150,000
+107,777
+255% +$2.26M
CMPX icon
87
Compass Therapeutics
CMPX
$387M
$3.34M 0.24%
+1,812,995
New +$2.26M
NKTX icon
88
Nkarta
NKTX
$172M
$2.94M 0.21%
650,000
+100,000
+18% +$568K
ELEV
89
DELISTED
Elevation Oncology
ELEV
$2.86M 0.2%
4,760,000
+1,700,000
+56% +$2.52M
KZR
90
DELISTED
Kezar Life Sciences
KZR
$2.81M 0.2%
+364,030
New +$2.2M
BOLT icon
91
Bolt Biotherapeutics
BOLT
$7.78M
$2.47M 0.18%
190,639
– –
FATE icon
92
Fate Therapeutics
FATE
$326M
$2.45M 0.18%
700,000
– –
CHRS icon
93
Coherus Oncology
CHRS
$196M
$2.44M 0.17%
2,350,000
+1,300,000
+124% +$1.78M
GMAB icon
94
Genmab
GMAB
$19.5B
$2.44M 0.17%
100,000
– –
TECX
95
Tectonic Therapeutic
TECX
$606M
$2.4M 0.17%
79,166
– –
SWTX
96
DELISTED
SpringWorks Therapeutics
SWTX
$2.38M 0.17%
+74,265
New +$2.77M
TGTX icon
97
TG Therapeutics
TGTX
$7.62B
$2.34M 0.17%
100,000
– –
TBPH icon
98
Theravance Biopharma
TBPH
$877M
$2.12M 0.15%
+262,896
New +$2.28M
KURA icon
99
Kura Oncology
KURA
$850M
$1.95M 0.14%
100,000
– –
IPSC icon
100
Century Therapeutics
IPSC
$361M
$1.54M 0.11%
900,000
– –
2 3
4
5 6

Similar funds

HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return

Tang Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Tang Capital Management held 162 positions worth $1.4B, up 43% from $982M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Tang Capital Management deployed $336M of net new capital in Q3 2024, opening 35 new positions and adding to 43 existing holdings. Its largest new stake was iTeos Therapeutics: 2,407,800 shares worth $24.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Dynavax Technologies, an estimated $6.61M trimmed.

  • Tang Capital Management's largest Q3 2024 buy was iTeos Therapeutics: 2,407,800 shares worth $24.6M.
  • Tang Capital Management added most to Aurinia Pharmaceuticals in Q3 2024, an estimated $27.6M increase.
  • Tang Capital Management's biggest Q3 2024 reduction was Dynavax Technologies, cutting an estimated $6.61M.
  • Tang Capital Management fully exited Eli Lilly in Q3 2024, selling an estimated $24.4M.
  • Tang Capital Management's ten largest holdings make up 36% of its $1.4B portfolio in Q3 2024.
  • Tang Capital Management opened 35 new positions and closed 8 in Q3 2024.
  • Tang Capital Management's portfolio value rose 43% quarter-over-quarter to $1.4B.

Based on Tang Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.